Moderna and Merck’s Shot Against Cancer [STAT Summit 2026 Review #25]

Report 25. Moderna and Merck’s Shot Against Cancer

Part I. English Version

1. Event / Date & Time

Event: Moderna and Merck’s Shot Against Cancer

Conference: STAT Summit 2026

Date & Time: October 15, 2026 | 11:15 AM EDT

2. Participants

Speakers

- Dean Y. Li, M.D., Ph.D. — Executive Vice President and President, Merck Research Laboratories

- Stephen Hoge, M.D. — President, Moderna

Moderator

- Matthew Herper — Senior Writer, Medicine; Editorial Director of Events, STAT

3. Summary

Personalized Immunotherapy: Moderna and Merck discussed using mRNA to encode patient-specific tumor neoantigens and stimulate immune responses alongside pembrolizumab.

Clinical Development Progress: The companies framed melanoma trial findings as an encouraging step while emphasizing the need for confirmatory evidence and broader development.

Partnership and Manufacturing: Individualized cancer vaccines depend on genomic analysis, rapid design and manufacturing, and close coordination between platform and oncology developers.

4. Main Discussion

From Neoantigen Hypothesis to a Personalized Vaccine

Li and Hoge explained that tumor-specific mutations can generate neoantigens distinguishable from normal tissues. An mRNA platform can encode selected neoantigens for a given patient, potentially eliciting T-cell responses when combined with the PD-1 inhibitor pembrolizumab. The concept contrasts with earlier cancer-vaccine approaches that did not use patient-specific mutation profiles.

The scientific premise involves teaching the immune system to recognize mutation-derived antigens from an individual patient’s tumor. The Moderna–Merck approach combines an mRNA product designed around that information with pembrolizumab, an established PD-1 checkpoint inhibitor. Executives situated the concept in a much longer history of unsuccessful or inconclusive cancer-vaccine efforts, arguing that improvements in sequencing, computing and mRNA design create new possibilities. They also reacted to the preceding video testimony from a melanoma trial participant, emphasizing that the eventual objective is patient benefit rather than a platform milestone. As discussed, a powerful scientific rationale does not itself establish benefit: the combination still has to be evaluated in the context of appropriate comparators, toxicity, patient selection and clinically meaningful outcomes.

Executives explained why the neoantigen approach differs from administering the same vaccine to every patient. The tumor contains mutations that may produce protein fragments recognizable by immune cells, but not every mutation is presented on the surface of cancer cells or elicits a useful T-cell response. Sequencing and computational ranking are therefore central to identifying a set of targets for an individualized mRNA construct. Hoge acknowledged that this approach confronts biological uncertainty rather than eliminating it; machine-learning tools help prioritize candidate antigens despite incomplete understanding. This framing cautions against assuming that personalization by itself guarantees activity or that a design algorithm can replace clinical evidence.

Clinical Evidence and Remaining Questions

The executives reviewed the trajectory from early trials to later-stage melanoma development and the significance of a positive Phase 3 program discussed during the event. They stressed that clinical development requires confirming meaningful patient benefit, identifying appropriate populations and understanding response variability. The preceding patient testimony illustrated what trial participation means beyond efficacy statistics.

The partnership was presented as an example of two capabilities that neither company could easily combine alone. Merck contributes immuno-oncology clinical-development experience and the checkpoint inhibitor, while Moderna provides a platform for rapid design of individualized mRNA constructs. A patient-specific process requires tumor tissue, sequencing, computational selection of antigens, manufacturing, quality testing and delivery back to the treating site. Each step introduces timing and logistical constraints; a universal batch-produced vaccine would operate very differently. The executives discussed the unusual problem of maintaining standardized manufacturing quality when the sequence of the product changes for each individual. Continued clinical enrollment, operational performance and access must therefore be considered together rather than treating personalized formulation as a minor variation of conventional drug production.

The speakers reflected on an unusually long history of attempts to turn the cancer-vaccine hypothesis into reliable patient benefit. The premise of immune recognition of tumors predates modern mRNA platforms by many decades; technological progress in tumor sequencing, immuno-oncology and individualized manufacturing has made a more precise test of that premise possible. Li emphasized that decisions made from early data require conviction but also discipline about what has and has not been established. Their remarks framed the Phase 3 program as a critical test of clinical value rather than a declaration that vaccines had solved melanoma. Changes in comparator treatment and clinical practice also complicate long development programs.

Design-to-Dose Operational Challenges

Personalization requires moving rapidly from tumor sampling and sequencing to computational antigen selection, vaccine design, manufacturing and delivery. The partnership brings together Moderna’s mRNA platform and Merck’s oncology development expertise. Participants acknowledged that scaling a patient-specific product differs substantially from manufacturing a conventional uniform medicine.

The executives characterized melanoma development as a testing ground rather than proof that the same platform will work in every malignancy. Tumor mutation burden, antigen presentation, immune suppression and disease stage can differ markedly; such biological features may influence whether neoantigen-directed vaccination elicits an effective response. Discussion of later-stage studies emphasized the value of data from larger and more diverse patient groups after initial signals. The companies described extensive tumor and molecular information collected through Phase 3 development, which may help refine subsequent research questions. However, correlates of immune response and commercial feasibility cannot be assumed from a single encouraging readout. The session therefore joined optimism about a new therapeutic category with explicit recognition of the clinical and operational unknowns.

Individual production introduces an operational burden that standardized immunotherapies do not face to the same degree. Tumor material must be collected and analyzed, target choices must be converted into a patient-specific sequence, and that sequence must pass manufacturing and quality controls before reaching the clinic. Even a promising product may become impractical if turnaround time is too long for the clinical treatment window or if capacity cannot expand with demand. The partners’ distinct strengths were presented as necessary for integrating these steps. Economic accessibility and compatibility with ordinary oncology practice remain questions for future implementation; the session did not supply a definitive cost or commercial production benchmark.

Platform Potential Beyond Melanoma

The speakers discussed how success in melanoma could inform development of personalized therapeutic vaccines in additional tumor types, while noting that different cancers pose distinct biological challenges. The platform’s future depends on reproducible clinical evidence as well as operational scalability and access.

Patient-centered translation remains distinct from successful laboratory design. The earlier patient account illustrated anxiety over eligibility, physical symptoms and the importance of continuous explanations from clinicians. Executives acknowledged that an individually manufactured oncology product must fit into real treatment timelines, including surgery, immunotherapy schedules, recurrence monitoring and clinical follow-up. They also discussed the need to learn from negative as well as positive observations as the program matures. The main industrial lesson was that precision treatment is a full development system spanning biomarkers, digital design, production, logistics, clinical evidence and patient support. Collaboration across those stages is as important as the underlying molecular innovation.

The partnership’s broader ambition involves learning whether the platform can be applied in malignancies with different immunologic profiles. Melanoma can offer a favorable environment for neoantigen studies, but more immune-resistant tumors may respond differently. Executives discussed the possibility of moving into other cancers while recognizing the need to prioritize trials and generate new evidence for each setting. The patient video shown immediately beforehand underscored that progress should ultimately be assessed through meaningful outcomes rather than sequence-design speed alone. Platform extensibility, regulatory evidence and the logistics of patient-specific delivery must advance together if the approach is to move beyond specialized trial centers.

5. Insights

Integrated Precision Oncology: Personalized mRNA therapies illustrate the need to link tumor genomics, immunology, clinical evidence and manufacturing in one development pathway.

Implications for South Korea: Korea could explore translational collaborations that connect cancer sequencing, neoantigen research and flexible clinical manufacturing capabilities.

Global Co-Development: Partnerships combining complementary platforms and clinical-development capabilities may accelerate precision cancer immunotherapy.

Report 25. Moderna and Merck’s Shot Against Cancer_eng.pdf

Download PDF • 67KB